Renaissance Technologies
VERV

Renaissance Technologies’s Verve Therapeutics VERV Stock Holding History

Renaissance Technologies’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,047,600
Closed -$11.8M – 3965
2025
Q2 		$11.8M Buy
1,047,600
+866,800
+479% +$4.94M 0.02% 972
2025
Q1 		$826K Sell
180,800
-182,600
-50% -$1.22M ﹤0.01% 2522
2024
Q4 		$2.05M Sell
363,400
-211,386
-37% -$1.19M ﹤0.01% 2040
2024
Q3 		$2.78M Buy
574,786
+100,286
+21% +$582K ﹤0.01% 1806
2024
Q2 		$2.32M Buy
474,500
+275,173
+138% +$1.73M ﹤0.01% 1790
2024
Q1 		$2.65M Buy
199,327
+34,760
+21% +$461K ﹤0.01% 1835
2023
Q4 		$2.29M Buy
+164,567
New +$2.04M ﹤0.01% 1870
2022
Q3 		– Sell
-311,200
Closed -$4.75M – 4433
2022
Q2 		$4.75M Buy
+311,200
New +$4.82M 0.01% 1601
2022
Q1 		– Sell
-24,000
Closed -$885K – 4489
2021
Q4 		$885K Buy
+24,000
New +$1.01M ﹤0.01% 2740

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Renaissance Technologies's VERV Position: Q3 2025 in Review

Renaissance Technologies sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 1,047,600 shares — an estimated $11.8M sold.

Renaissance Technologies first reported a position in VERV in Q4 2021 and held it in 9 quarters. The position peaked at $11.8M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Renaissance Technologies reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Renaissance Technologies sold 1,047,600 Verve Therapeutics shares in Q3 2025, an estimated $11.8M.
  • Renaissance Technologies first reported a position in Verve Therapeutics in Q4 2021 and held it in 9 quarters.
  • Renaissance Technologies's Verve Therapeutics position peaked at $11.8M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.